> NBQX, (Ascent Scientific) a competitive AMPAR receptor antagonist, and AP5 (Ascent Scientific) a competitive NMDAR antagonist were dissolved in sterile 0.9% saline solution and infused at 1 and 25 mM/side, respectively.
Stable clones were routinely passaged onto MMC-treated CF-1 feeder cells (Globalstem) using 1 mg/ml collagenase type IV (Invitrogen) and addition of 10 µM Y-27632 (Ascent Scientific) for the first 48 h after passaging.
Forskolin was from Ascent scientific (Bristol, UK).
Paclitaxel from Ascent Scientific (Weston-SuperMare, UK), a standard drug used in chemotherapy regimen for prostate cancer was used as positive control in this study.
Kainic acid (Ascent scientific, Bristol, UK) was dissolved in 0.9% saline and administered (30 mg/kg; i.p). in a volume of 10 ml/kg body weight to induce epileptiform seizures.
4-Aminopyridine (4-AP), was purchased from Tocris Bioscience (Bristol, UK), kainate from Ascent Scientific (Weston-Super-Mare, UK); tetraethylammonium (TEA) and other chemicals were purchased from Sigma-Aldrich (Lyon, France).
Drugs used were purchased from Sigma-Aldrich (Stockholm, Sweden) or Ascent Scientific (Weston-Super-Mare, UK).
AMPA, cyclothiazide (CTZ) and ryanodine were obtained from Ascent Scientific (Bristol, UK).
SRPIN340 (N-[2- 1-piperidinyl -5- trifluoromethyl phenyl] isoN-[2- 1-piperidinyl -5- trifluoromethyl phenyltific, Bristol, UK.
Glutamate and GABAA receptor antagonists were obtained from Tocris (Bristol, UK) or Ascent Scientific (Bristol, UK).
